Rezvilutamide

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Prostate CancerAndrogen Deprivation Therapy

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

1

Antiandrogen Therapy

UUniversity of Washington

Phase 3

102

AAA817

Novartis

Phase 3

13

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

34

Androgen Deprivation Treatment

MMedical University of Vienna

Phase 3

15

SHR3680

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

56

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

27

Rezvilutamide

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

78

Trexall

Jazz Pharmaceuticals

Preclinical

—9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

110

Duragesic

CCephalon

Preclinical

1Show 20 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Prostate Cancer7 trials

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05753566·96 enrolled

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06305832·102 enrolled

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Not yet recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1/2·NCT07407283·100 enrolled

Show 4 more trials

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT07241416·156 enrolled

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05406999·900 enrolled

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Not yet recruiting·JJianbin Bi·Phase 2·NCT06134271·160 enrolled

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT06387056·40 enrolled

First Line Therapy1 trial

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Completed·FFirst Affiliated Hospital of Wenzhou Medical University··NCT07428642·168 enrolled

Androgen Deprivation Therapy1 trial

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Recruiting·PPeking University First Hospital·Phase 2·NCT06348264·37 enrolled

Efficacy and Safety1 trial

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT05983783·200 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Recruiting·AstraZeneca·Phase 3·NCT07611110·670 enrolled

Details

Drug Info

Related News